HLA-A and myeloid sarcoma: These observations led us to hypothesize that the lower risk of developing MS in HLA-A*02+ subjects carrying the β1i HH60 variant could be—at least in part—due to a lower production of MBP111–119 by oligodendrocytes or APCs in these subjects [22].